Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > ARCHIVE
ARCHIVE
- BUSINESS NEWS IN BRIEF -2-
October 15, 2001
- Aiming at \300 Bil. Sales in FY2006: Mr Nagasaka of Banyu
October 15, 2001
- Taiho: Sales Up 3.9% to \96.4 Bil.
October 15, 2001
- Ribavirin, INF Combination Recommended for Approval for Hepatitis C
October 15, 2001
- Shionogi to Need 2 Years Before Obtaining Results of Restructuring
October 8, 2001
- Number of Diabetes Patients to Increase to 4.3 Mil. in 2010: Mr Nagae of Aventis
October 8, 2001
- BUSINESS NEWS IN BRIEF -1-
October 8, 2001
- BUSINESS NEWS IN BRIEF -2-
October 8, 2001
- Gastric Cancer Closely Linked with H. pylori Infection: Seminar
October 8, 2001
- Bill for Healthcare Reform to Be Presented to Diet Next Year -1-
October 8, 2001
- Losartan Shows Renal Protective Effects: NEJM
October 8, 2001
- WORLD NEWS IN BRIEF
October 8, 2001
- AIST, Toyo Shinyaku to Screen Plant Extracts That Kill Leukemia Cells
October 8, 2001
- Bill for Healthcare Reform to Be Presented to Diet Next Year -3-
October 8, 2001
- JPMA, ABPI Deepen R&D Exchanges
October 8, 2001
- Bill for Healthcare Reform to Be Presented to Diet Next Year -4-
October 8, 2001
- DIAGNOSTIC NEWS IN BRIEF
October 8, 2001
- Dr Kurokawa Explains Background for Proposed PAL Amendment
October 8, 2001
- JMA, Hospital Associations Confirm Opposition to Operation of Hospitals by Private Companies
October 8, 2001
- REGULATORY NEWS IN BRIEF
October 8, 2001
ページ
Japan’s pharmaceutical industry is undergoing a structural shift in its workforce, with the role of sales reps shrinking while production…
In the complex landscape of the Japanese pharmaceutical market, the “status quo” is often the safest harbor. But for leaders like Kennet Brysting, former president of Gilead Japan, the status quo is the most dangerous place to stay.Innovation in Japan…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…